Citations

Clear

34 citation(s) found for "Sasaki, S".

Homocysteine increases phosphorylation and aggregation of α-synuclein
Enomoto, Soichi, Asano, Rei, Sasaki, Hirohito, Yamaguchi, Tomohisa, Kitazaki, Yuki , Endo, Yoshinori, Shirafuji, Norimichi, Yen, Shu-Hui, Onishi, Hidenori, Yamamura, Osamu , Aoki, Koji, Okuro, Masashi , Nakamoto, Yasunari , Nishiyama, Yasuhiro, Hamano, Tadanori , Endo, Yoshinori , Sawai, Yasuhisa , Nakano, Hiroyuki , Ikawa, Masamichi

Mayo Clinic

Journal of Clinical Biochemistry and Nutrition | March 10, 2026 | Volume: 78 | Issue: 3 | Pages: 259-267

10.3164/jcbn.25-119 | PMID 42182943 Get It

AAOS OrthoInfo provides more accessible information regarding femoroacetabular impingement than ChatGPT-4 while information accuracy is comparable
Sasaki, Jared , Hand, Catherine, Feroe, Aliya G. , McMaster, Brandon, Lu, Yining , Forsythe, Brian, Okoroha, Kelechi R. , Hassan, Mahad M. , Forsythe, Brian , Forsythe, Brian , Hand, Catherine , Ulrich, Marisa N.

Mayo Clinic

Journal of Hip Preservation Surgery | January 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/jhps/hnag001 Get It

Abstract As artificial intelligence (AI) Large Language Models (LLM) like ChatGPT become more common in healthcare, patients increasingly use them to find medical information. While ChatGPT may support health literacy, its readability and accuracy compared to established resources remain unclear. The purpose of this study is to evaluate ChatGPT-4 responses on femoroacetabular impingement (FAI) and its surgical management compared to AAOS OrthoInfo content. We hypothesize that ChatGPT may deliver medically accurate information, but its readability may fall short when compared to OrthoInfo. Nine questions based on the OrthoInfo FAI page were submitted to ChatGPT-4, with and without a readability prompt. Topics included anatomy, pathology, cause, symptoms, workup, imaging, treatment, role of hip arthroscopy, and outcomes. Readability was assessed using validated indices. Accuracy was independently rated using a 4-point scale. Statistical comparisons were made using t-tests and ANOVA (P < 0.01 threshold). OrthoInfo content had a mean reading grade level of 8.0 and a Flesch Reading Ease score of 60.7. Unprompted ChatGPT responses were significantly less readable (grade level 16.2; Flesch score 21.7; P < 0.001). Prompting for readability improved ChatGPT outputs (grade level 10.6; Flesch score 58.2), making them comparable to OrthoInfo (P < 0.09). Accuracy was high across all sources, though OrthoInfo's response on FAI causes scored slightly lower (3.5 versus 4.0; P < 0.46). ChatGPT provides accurate information on FAI. However, without prompting, its complexity may hinder patient understanding. Prompting for readability enables ChatGPT to match established resources like OrthoInfo. Tailored prompting is key to using LLM effectively in patient education and promoting health literacy.
Clinical and biological correlates of blast-transformed chronic myelomonocytic leukemia (CMML): A multicenter study of 493 paired cases at chronic phase and at blast transformation
Montalban‐Bravo, Guillermo , Cysique-Foinlan, Leila , Finke, Christy M. , Al‐Kali, Aref , Alsugair, Ali, Begna, Kebede, Fathima, Saubia, Gangat, Naseema , Mangaonkar, Abhishek A. , Tefferi, Ayalew , Morabito, Margot, Marzac, Christophe , Braun, Thorsten, Adès, Lionel, Bazinet, Alexandre , Chien, Kelly S. , Kadia, Tapan M. , Kanagal‐Shamanna, Rashmi , Pemmaraju, Naveen , Kantarjian, Hagop, Fenaux, Pierre , Garcia‐Manero, Guillermo , Patnaik, Mrinal M. , Kanagal-Shamanna, Rashmi , Csizmar, Clifford M. , Natu, Anuya , Lasho, Terra L. , Alkhateeb, Hassan B. , Fathima, Saubia , Saliba, Antoine N. , Droin, Nathalie , Quivoron, Cyril , Podvin, Benjamin , Duployez, Nicolas , Kosmider, Olivier , Thépot, Sylvain , Meunier, Mathieu , Berthon, Céline , Braun, Thorsten , Willekens, Christophe , Botton, Stéphane de , Adès, Lionel , Hammond, Danielle , DiNardo, Courtney D. , Loghavi, Sanam , Ravandi, Farhad , Sasaki, Koji , Solary, Éric , Renneville, Aline

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 2081-2081

10.1182/blood-2025-2081 Get It

Abstract Introduction Blast transformation (BT) in CMML occurs in 15-30% of patients (pts) with a median overall survival (OS) <6 months (mo). While clonal evolution can be observed, biological mechanisms of BT remain unknown for many pts. Using paired samples from chronic phase (CP) and at BT, this study defines the cytogenetic and molecular landscape of BT-CMML. Methods BT-CMML pts from Mayo Clinic (n=153, 31%), MD Anderson (n=195, 40%), and 7 centers of the Groupe Francophone des Myélodysplasies (n=145, 29%) were included after IRB approval. ICC 2022 criteria defined CMML and AML. Pt data were collected at initial diagnosis or referral at CP and again at BT. Clonal dominance was inferred from a natural log-fold difference of mutation variant allele fractions (VAF). OS was censored at allogeneic stem cell transplant (alloSCT). Single-cell multiomic analyses used the Tapestri platform (Mission Bio). Statistics used R. Results Among 1,883 cases of CMML with a median follow up of 96 mo, 493 (26%) underwent BT. The median age at CP and BT was 69 and 71 years, respectively. BT-CMML pts were predominantly male (69%) and had proliferative CMML (53%) or CMML-1 (69%) in CP; 39% and 33% were considered high-risk by CPSS-Mol and BLAST-Mol criteria, respectively. The median time to BT was 16 mo (interquartile range 7-35 mo) and was not different in males vs females (p=0.60). Compared to their CP parameters (p<0.001 each), pts at BT had lower median hemoglobin (10.8 vs 9.2 g/dL) and platelets (100 vs 44 x109/L) but higher leukocytes (13.9 vs 16.3 x109/L), peripheral blasts (0% vs 14%), and bone marrow blasts (6% vs 32%). Blasts exhibited mostly monocytic (57%) or immature myeloid (40%) differentiation. Abnormal karyotypes (AK) were more prevalent at BT (25% vs 62%, p<0.001). Among 318 pts with paired karyotype data, 221 (69%) had a normal karyotype (NK) in CP, of which 123 (56%) remained normal at BT and 98 (44%) acquired new abnormalities. Conversely, 97 (31%) pts had an AK in CP, of which 67 (69%) acquired abnormalities or increased clonal metaphases (6%), 23 (24%) remained stable, and 7 (7%) reverted to a NK at BT. Overall, 46% acquired and 8% lost a clonal cytogenetic abnormality, while 46% remained unchanged. Numeric (37%) and structural (30%) changes were most common. Complex (12% vs 3%) and monosomal (5% vs 2%) karyotypes were more frequent at BT than in CP. Only 6 (2%) pts acquired an AML-defining rearrangement at BT. Mutational data were available for 248 paired cases. The number of somatic mutations was higher at BT (median 3 vs 4, p<0.001). Mutations in RUNX1 (27% vs 39%), NRAS (23% vs 33%), KRAS (11% vs 17%), FLT3 (6% vs 15%), NPM1 (0% vs 11%), IDH2 (5% vs 11%), and CEBPA (3% vs 10%) were more frequent at BT (all p<0.05). At BT, the average VAF of the dominant clone increased in 32%, decreased in 35%, and remained unchanged (delta ≤5%) in 33%. The most frequent dominant clones both in CP and at BT had mutations in TET2 (8% vs 4%) or co-dominant mutations involving SRSF2-TET2 (7% vs 3%). Mutational clonal evolution was observed in 72%, with mutations gained in 45% and lost from the dominant clone in 19%. The most gained mutations at BT were in NRAS (15%) and RUNX1 (13%). Single cell proteogenomic analyses in 4 selected CP and BT pts shed light on the impact of NRAS and RUNX1 mutations on clonal hierarchies and differentiation. Among 196 fully evaluable cases, a new cytogenetic and/or molecular aberration was uniquely gained in 106 (54%) cases and lost in 9 (5%), with 40 (20%) both gaining and losing a genetic alteration. Forty-one (21%) patients had no identifiable genetic change between CP and BT, suggesting driver alterations outside of that detected by routine analyses. Median OS was 31 mo from CMML diagnosis and 5.6 mo from BT. Compared to supportive care, treatment in CP did not prolong median time to BT (14 vs 17 mo, p=0.91) or OS (35 vs 29 mo, p=0.05), regardless of intensity. After BT, median OS was 1.2 mo with supportive care (n=83), 8.7 mo with a hypomethylating agent (HMA, n=39), 10 mo with HMA plus venetoclax (n=37), 7.8 mo with chemotherapy (n=91), and 31 mo in pts who underwent alloSCT (n=57). Conclusions In this large BT-CMML cohort, cytogenetic (46% gained, 8% lost) or mutational (45% gained, 19% lost) driver events were identified in 79% of pts, with 21% having no identifiable changes by conventional testing. Whole genome/transcriptome analyses are underway in this subgroup to identify novel drivers of BT.
Optimizing liver transplant outcomes for colorectal liver metastases in the United States
Chávez‐Villa, Mariana , Sasaki, Kazunari , Nakayama, Toshihiro , Byrne, Matthew , Jiménez-Soto, Cristina , Ruffolo, Luis I. , Endo, Yutaka , Dokus, M. Katherine , Bekki, Yuki , Qadan, Motaz , Tomiyama, Koji , Roberts, J.P., Byrne, Matthew M , Roberts, John P , Pomfret, Elizabeth , Wall, Anji E , Hernández-Alejandro, Roberto , Wall, Anji , Chavez-Villa, Mariana

Mayo Clinic

Liver Transplantation | October 14, 2025 | Volume: 32 | Issue: 4 | Pages: 508-517

10.1097/lvt.0000000000000746 | PMID 41086433 Get It

The TransMet trial and Norwegian studies have shown excellent outcomes in highly selected patients undergoing liver transplant (LT) for unresectable colorectal liver metastases (uCRLM). Our aim is to provide an updated analysis of the current state of LT for uCRLM in the United States. Adult patients with a diagnosis of uCRLM listed for LT between December 2017 and March 2025 were identified from the United Network for Organ Sharing database and analyzed. An analysis of living donor LT (LDLT) and deceased donor LT (DDLT) was performed. During this period, 222 patients were listed, and 158 received an LT across 33 centers. Of these, 76 (48.1%) underwent LDLT, and 82 patients (51.9%) underwent DDLT. Of the 82 deceased donors, 56 (68.2%) were out-of-sequence offers. Overall, the 3-year survival and disease-free survival rates were 66.7% and 44.0%, respectively. The 3-year survival for LDLT and DDLT was 74.1% and 57.3% ( p =0.04), respectively. While these results have not yet reached the acceptable threshold established for other LT indications, they have improved and are expected to continue improving after the implementation of prioritization points. Given the potential variability of oncologic selection criteria and graft quality, we call for the standardization of nationally accepted selection criteria for listing patients for LT with uCRLM and for providing early access to high-quality organs. To achieve this, it is imperative to create, update, and maintain national databases that allow for the collection of more granular oncological variables.
Landscape and clinicopathologic features of RAS pathway mutations in chronic myelomonocytic leukemia
Montalban‐Bravo, Guillermo , Loghavi, Sanam , Li, Ziyi , Chien, Kelly S. , Kanagal‐Shamanna, Rashmi , Natu, Anuya , Gurney, Mark E. , Bazinet, Alexandre , Sasaki, Koji , Kadia, Tapan M. , Ravandi, Farhad, Pemmaraju, Naveen , Finke, Christy M. , Al‐Kali, Aref , Gangat, Naseema , Mangaonkar, Abhishek A. , Bueso‐Ramos, Carlos E. , Tefferi, Ayalew, Kantarjian, H., Garcia‐Manero, Guillermo , Patnaik, Mrinal M. , Kantarjian, Hagop M. , Chien, Kelly , Gurney, Mark , Sasaki, Koji , DiNardo, Courtney , Daver, Naval , Short, Nicholas , Pemmaraju, Naveen , Issa, Ghayas , Al-Kali, Aref , Csizmar, Clifford , Gangat, Naseema , Patnaik, Mrinal , Loghavi, Sanam , Kanagal-Shamanna, Rashmi , Kantarjian, Hagop , Bataller, Alex , Hammond, Danielle , Borthakur, Gautam , Swaminathan, Mahesh , DiNardo, Courtney D. , Ravandi, Farhad , Daver, Naval , Short, Nicholas J. , Lasho, Terra L. , Csizmar, Clifford M. , Alkhateeb, Hassan B. , Tefferi, Ayalew

Mayo Clinic

Blood Advances | July 11, 2025 | Volume: 9 | Issue: 19 | Pages: 5105-5117

10.1182/bloodadvances.2025016529 | PMID 40644618 Get It

Abstract RAS pathway (RASp) mutations induce proliferative features, and promote transformation in chronic myelomonocytic leukemia (CMML). However, the unique clonal landscape and hierarchy of distinct RASp mutations remain unexplored. To characterize the landscape, architecture, and implications of unique RASp mutations in CMML, we evaluated a cohort of 814 patients with CMML. We identified 461 RASp mutations among 342 patients (42%). N/KRAS and CBL mutations were the most common, frequently involved the P-loop or RING domains, respectively, and frequently appeared as dominant events (63% and 65%, respectively). BRAF, NF1, and PTPN11 mutations spanned throughout the gene structure, and frequently appeared as subclonal events (75%, 64%, and 59%, respectively). CBL mutations frequently occurred in codominance with SRSF2 and multihit TET2, and were enriched for KIT mutations. PTPN11 mutations more frequently co-occurred with SETBP1 and DNMT3A mutations, and were infrequently codominant with TET2 or ASXL1. RASp mutations predicted for shorter overall survival (hazard ratio [HR], 1.55; 95% confidence interval [CI], 1.15-2.07; P = .0075) and leukemia-free survival (LFS; HR, 1.67; 95% CI, 1.26-2.20; P = .0011), influenced outcomes of myelodysplastic and TET2 mutant CMML, and cooperated with IDH2 and RUNX1 mutations to induce shorter LFS. These data set the bases for refined genomic classifications of CMML, and underscore the need to develop RAS-directed therapies for patients with CMML.
EUS-guided hepaticogastrostomy versus single balloon enteroscopy-assisted endoscopic retrograde cholangiopancreatography for malignant biliary obstruction in patients with surgically altered anatomy
Igarashi, Tsuyoshi, Yamaguchi, Shota , Inoue, Kanae , Taira, Tomonao , Watanabe, Kazuo , Sasaki, Mitsuhito , Mitsunaga, Shuichi , Shibuki, Taro , Fukami, Norio , Satake, Tomoyuki , Imaoka, Hiroshi , Gotohda, Naoto , Ikeda, Masafumi

Mayo Clinic

Endoscopic Ultrasound | July 4, 2025 | Volume: 14 | Issue: 4 | Pages: 196-204

10.1097/eus.0000000000000130 | PMID 41583371 Get It

ABSTRACT Background and objective Endoscopic retrograde cholangiopancreatography (ERCP) is the gold standard for managing malignant biliary obstruction (MBO), but it is challenging in patients with surgically altered anatomy (SAA). EUS-guided hepaticogastrostomy (EUS-HGS) and enteroscopy-assisted ERCP are alternative techniques, but their comparative efficacy and safety in this population are not well-researched. Herein, we evaluated the outcomes of EUS-HGS versus single-balloon–assisted enteroscopy ERCP (SBE-ERCP) in MBO patients with SAA. Patients and methods This retrospective study included 70 patients with MBO who underwent EUS-HGS (n = 29) or SBE-ERCP (n = 41) at a single center between April 2015 and June 2024. Data on the patient characteristics, procedure details, time to recurrent biliary obstruction (TRBO), and adverse events (AEs) were analyzed. Results The EUS-HGS group showed a higher technical success rate (100% vs. 68%, P = 0.002), shorter procedure time (23 vs. 50 min, P < 0.001), and longer TRBO (251 vs. 103 d, P = 0.020) as compared with the SBE-ERCP group. Subgroup analysis revealed that pancreatobiliary cancer and SBE-ERCP were significantly associated with a shorter TRBO. When stratified by stent type, the median TRBO in the SBE-ERCP with PS group was 49 days, serving as the reference. In comparison, the median TRBO was 140 days in the SBE-ERCP with the self-expandable metallic stent group (hazard ratio [HR], 0.46; P = 0.181), 127 days in the EUS-HGS with PS group (HR, 0.38; P = 0.055), and 701 days in the EUS-HGS with the self-expandable metallic stent group (HR, 0.13; P = 0.014). The overall incidence of AEs was comparable between the 2 groups (20.6% vs. 17.1%), and there were no severe AEs. Regarding reintervention, there was no significant difference in technical success rate and procedure time between EUS-HGS and SBE-ERCP. Conclusion EUS-HGS was associated with a superior technical success rate, shorter procedure time, and longer stent patency, without an increased risk of AEs, as compared with SBE-ERCP. Thus, EUS-HGS should be appropriate for managing MBO patients with SAA.
BLAST: A Globally Applicable and Molecularly Versatile Survival Model for Chronic Myelomonocytic Leukemia
Tefferi, Ayalew , Fathima, Saubia , Abdelmagid, Maymona, Alsugair, Ali, Aperna, Fnu, Rezasoltani, Mahsa , Yousuf, Muhammad , Natu, Anuya , Csizmar, Clifford M. , Gurney, Mark E. , Finke, Christy M. , Chien, Kelly S. , Bazinet, Alexandre , Kadia, Tapan M. , Mangaonkar, Abhishek A. , Pardanani, Animesh , Zepeda‐Mendoza, Cinthya , Reichard, Kaaren K. , He, Rong , Sasaki, Koji , Garcia‐Manero, Guillermo , Gangat, Naseema , Montalban‐Bravo, Guillermo , Patnaik, Mrinal M. , Alsugair, Ali Khalid A, Gurney, Mark , Kanagal-Shamanna, Rashmi , Hammond, Danielle , Chien, Kelly , DiNardo, Courtney , Daver, Naval , Zepeda-Mendoza, Cinthya, He, Rong , Loghavi, Sanam , Sasaki, Koji , Larson, Dirk , Onida, Francesco , Gangat, Naseema , Patnaik, Mrinal , Csizmar, Clifford , Fathima, Saubia , Lasho, Terra L. , Kanagal‐Shamanna, Rashmi , Hammond, Danielle , DiNardo, Courtney D. , Daver, Naval , Borthakur, Gautam , Loghavi, Sanam , Passamonti, Francesco , Ravandi, Farhad , Larson, Dirk R.

Mayo Clinic

Blood Journal | May 7, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/blood.2024027170 | PMID 40332442 Get It

We sought to develop a survival model in chronic myelomonocytic leukemia (CMML) that is primarily based on clinical variables and examine additional impact from mutations and karyotype. 457 molecularly-annotated patients were considered. Multivariable analysis identified circulating Blasts ≥2% (1 point), Leukocytes ≥13 x 109/L (1 point), and severe (2 points) or moderate (1 point) Anemia as preferred risk variables in developing a clinical risk Stratification Tool for overall survival (OS), acronymized to "BLAST": low-risk (0 points; median 63 months); intermediate-risk (1 point; median 28 months; HR 2.2, 95% CI 1.6-3.0), and high-risk (2-4 points; median 13 months; 5.4, 4.1-7.3); the corresponding 3/5 year OS rates were 68%/53%, 43%/18%, and 12%/1%. BLAST model performance (AUC 0.77/0.85 at 3/5-years) was shown to be comparable to that of the molecular CMML-specific prognostic scoring system (CMML-mol; AUC 0.73/0.75) and the international prognostic scoring system-molecular (IPSS-M; AUC 0.73/0.74). Multivariable analysis of mutations and karyotype identified PHF6MUT and TET2MUT as being "favorable" and DNMT3AMUT, U2AF1MUT, BCORMUT, SETBP1MUT, ASXL1MUT, NRASMUT, PTPN11MUT, RUNX1MUT, TP53MUT, and adverse karyotype, "unfavorable". Molecular information was subsequently encoded in a combined clinical-molecular risk model (BLAST-mol; AUC 0.80/0.86 at 3/5-years) that included the aforementioned BLAST clinical risk variables and a 3-tiered molecular risk score. BLAST and BLAST-mol were subsequently validated by two separate external cohorts. Independent risk factors for blast transformation included DNMT3AMUT, ASXL1MUT, PHF6WT, leukocytes ≥13 x 109/L, and ≥2% circulating or ≥10% bone marrow blasts. The current study proposes an easy to implement, globally applicable, and molecularly adaptive risk model for CMML.
Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia
Rankin, Alexander W. , Hoang, Chloe, Semchenkova, Alexandra , Myers, Regina M. , Wang, Hao‐Wei , Kovach, Alexandra E. , Yuan, Constance M. , Colon, Dana Delgado, Vasseur, Loïc , John, Samuel , Lyons, Kaylyn Utley , Friedes, Barbara D., Alonso‐Saladrigues, Anna , Abdel‐Azim, Hisham , Balducci, Estelle , Aljudi, Ahmed Assim , Balsat, Marie , Biery, D. N. , Chamdin, Aghiad, Cuevo, Raymund S., Dickens, David S. , Duffner, Ulrich, Elliott, Michelle A. , Escherich, Gabriele , Fernandes, Sneha, Fitzjohn, Mandi R., Gahvari, Zhubin, He, Rui , Harrison, Cynthia , Hergott, Christopher A. , Hsieh, Emily M. , Larson, Daniel P. , Lee, Benjamin J. , Leguay, Thibaut , Mangaonkar, Abhishek A. , Mezger, Kerstin, Pacenta, Holly , Provost, Marlie R. M., Puri, Latika, Raikar, Sunil S. , Martinez, Armando, Bristol, Isabella Quijada, Murphy, Kyle, Reiman, Lauren T. , Redell, Michele S. , Reed, Kelly, Guépin, Gabrielle Roth, Savaşan, Süreyya , Schafernak, Kristian T. , Stevens, Alexandra M. , Talleur, Aimee C. , Carapia, Naomi Torres, Vargaftig, Jacques , Vatsayan, Anant , Wölfl, Matthias , Rives, Susana , Sasaki, Koji , Davis, Kara L. , Ghorashian, Sara , Jacoby, Elad , Попов, А. М. , Lamble, Adam J. , Rankin, Alexander W , Semchenkova, Alexandra , Myers, Regina M , Zerkalenkova, Elena , Wang, Hao-Wei , Kovach, Alexandra E , Yuan, Constance M , Vasseur, Loïc , Alonso-Saladrigues, Anna , Balducci, Estelle , Aljudi, Ahmed Assim , Chang, Bill H , Cuevo, Raymund S , De Moerloose, Barbara , Dickens, David S , Duployez, Nicolas , Elliott, Michelle Ann, Harrison, Cynthia , Kim, Annette S , Kuo, Dennis J , Larson, Daniel P , Lee, Benjamin J , Leguay, Thibaut , Lindsley, R Coleman , Puri, Latika , Raikar, Sunil S , Rubinstein, Jeremy , Schafernak, Kristian , Talleur, Aimee , Vatsayan, Anant , Wölfl, Matthias , Rives, Susana , Fabrizio, Vanessa A , Sasaki, Koji , Boissel, Nicolas , Rheingold, Susan R , Davis, Kara L , Ghorashian, Sara , Popov, Alexander , Shah, Nirali N , Silbert, Sara K. , Zerkalenkova, Elena , Colon, Dana Delgado, Bataller, Alex , Biery, D. Nathan, Chaer, Firas El , Grupp, Stephan A. , Pan, Jing , Martinez, Armando, Murphy, Kyle, Zhao, Liping, Aldoss, Ibrahim

Mayo Clinic

Blood | April 7, 2025 | Volume: 146 | Issue: 4 | Pages: 437-455

10.1182/blood.2024026655 | PMID 40193715 Get It

Abstract Lineage switch (LS), defined as the immunophenotypic transformation of acute leukemia, has emerged as a mechanism of relapse after antigen-targeted immunotherapy, which is associated with dismal outcomes. Through an international collaborative effort, we identified cases of LS after a host of antigen-targeted therapies (eg, CD19, CD22, CD38, and CD7), described how LS was diagnosed, reviewed treatment approaches, and analyzed overall outcomes for this form of postimmunotherapy relapse. Collectively, 75 cases of LS were evaluated, including 53 (70.7%) cases of B-cell acute lymphoblastic leukemia (B-ALL) transforming to acute myeloid leukemia (AML), 17 (22.7%) cases of B-ALL transforming to mixed phenotypic acute leukemia (MPAL)/acute leukemias of ambiguous lineage (ALAL), and 5 (6.7%) cases of rare LS presentation (ie, T-cell ALL to AML). An additional 10 cases with incomplete changes in immunophenotype, referred to as “lineage drift” were also described. With a primary focus on the 70 cases of LS from B-ALL to AML or MPAL/ALAL, LS emerged at a median of 1.5 months (range, 0-36.5) after immunotherapy, with 81.4% presenting with LS within the first 6 months from the most proximal immunotherapy. Although most involved KMT2A rearrangements (n = 45, 64.3%), other rare cytogenetic and/or molecular alterations were uniquely observed. Treatment outcomes were generally poor, with remission rates of &lt;40%. The median overall survival after LS diagnosis was 4.8 months. Outcomes were similarly poor for those with rare immunophenotypes of LS or lineage drift. This global initiative robustly categorizes lineage changes after immunotherapy and, through enhanced understanding, establishes a foundation for improving outcomes of LS.
Germline Pathogenic DROSHA Variants Are Linked to Pineoblastoma and Wilms Tumor Predisposition
Fiorica, Peter N. , Golmard, Lisa , Kim, Jung , Bao, Riyue , Lin, Frank Y. , Roy, Angshumoy , Pribnow, Allison , Perrino, Melissa R. , Masliah‐Planchon, Julien , Michalak-Provost, Sophie , Wong, Jennifer , Filser, Mathilde , Bourdeaut, Franck , Brahimi, Afane, Ingster, Olivier, Jackson, Sarah A. , Sasaki, Mark M. , Fowler, Trent, Ng, Anita , Corbett, Ryan J. , Kaufman, Rebecca , Haley, Jeremy S. , Carey, David J. , Huang, Kuan‐lin , Diskin, Sharon J. , Al‐Kateb, Hussam , Schultz, Kris Ann P. , Onel, Kenan , Stoppa-Lyonnet, Dominique , Bourdeaut, Franck , Brahimi, Afane , Ingster, Olivier , Saulnier Sholler, Giselle , Jackson, Sarah A , Sasaki, Mark M , Fowler, Trent , Ng, Anita , Corbett, Ryan J , Kaufman, Rebecca S , Haley, Jeremy S , Carey, David J , Huang, Kuan-Lin , Diskin, Sharon J , Rokita, Jo Lynne , Al-Kateb, Hussam , McGee, Rose B , Schiffman, Joshua D , Chen, Kenneth S , Stewart, Douglas R , Parsons, D Williams , Plon, Sharon E. , Schultz, Kris Ann P , Onel, Kenan , Perrino, Melissa R , Lin, Frank Y , Stoppa‐Lyonnet, Dominique , Rokita, Jo Lynne , Chen, Kenneth , Parsons, D. Williams

Mayo Clinic

Clinical Cancer Research | February 24, 2025 | Volume: 31 | Issue: 8 | Pages: 1491-1503

10.1158/1078-0432.ccr-24-2785 | PMID 39992227 Get It

Abstract Purpose: DROSHA, DGCR8, and DICER1 regulate miRNA biogenesis and are commonly mutated in cancer. Although DGCR8 and DICER1 germline pathogenic variants (GPV) cause autosomal dominant tumor predisposition, no association between DROSHA GPVs and clinical phenotypes has been reported. Experimental Design: After obtaining informed consent, sequencing was performed on germline and tumor samples from all patients. The occurrence of germline DROSHA GPVs was investigated in large pediatric and adult cancer datasets. The population prevalence of DROSHA GPVs was investigated in the UK Biobank and Geisinger DiscovEHR cohorts. Results: We describe nine children from eight families with heterozygous DROSHA GPVs and a diagnosis of pineoblastoma (n = 8) or Wilms tumor (n = 1). A somatic second hit in DROSHA was detected in all eight tumors analyzed. All pineoblastoma tumors analyzed were classified as miRNA processing–altered 1 subtype. We estimate the population prevalence of germline DROSHA loss-of-function variants to be 1:3,875 to 1:4,843 but find no evidence for increased adult cancer risk. Conclusions: This is the first report of DROSHA-related tumor predisposition. As pineoblastoma and Wilms tumor are also associated with DICER1 GPVs, our results suggest that the tissues of origin for these tumors are uniquely tolerant of general miRNA loss. The miRNA processing–altered 1 pineoblastoma subtype is associated with older age of diagnosis and better outcomes than other subtypes, suggesting DROSHA GPV status may have important clinical and prognostic significance. We suggest that genetic testing for DROSHA GPVs be considered for patients with pineoblastoma, Wilms tumor, or other DICER1-/DGCR8-related conditions and propose surveillance recommendations through research studies for individuals with DROSHA GPVs.
DEK::AFF2 Fusion Sinonasal and Skull Base Nonkeratinizing Squamous Cell Carcinoma
Hart, Stephanie A , Mikula, Michael W. , Amin, Sara E. , Saluja, Karan , Chen, Y., David, Stephanie N., Dupont, William D., Plummer, W. Dale, Ferrer, Karen, Geromes, Ariana, Hsieh, Min-Shu, Kuo, Ying‐Ju , Sasaki, Eiichi , Shi, Qiuying , Truong, Tra , Lewis, James S. , Lewis, James S , Hang, Jen‐Fan , Chernock, Rebecca , Rooper, Lisa M. , Bishop, Justin A. , Cipriani, Nicole A. , Hsieh, Min‐Shu , Hernandez‐Prera, Juan C. , Torres, Jaylou M. Velez

Mayo Clinic

American Journal of Surgical Pathology | December 25, 2024 | Volume: 49 | Issue: 2 | Pages: 130-137

10.1097/pas.0000000000002335 | PMID 39719672 Get It

DEK::AFF2 fusion nonkeratinizing squamous cell carcinoma (NKSCC) is an emerging entity in the sinonasal tract, temporal bone, and skull base. However, the clinical behavior of these tumors has not been well studied. Here, we report the largest cohort of DEK::AFF2 carcinomas to determine if morphology, mitotic rate, and/or Ki-67 IHC are associated with patient outcomes, including a comparison with high-risk human papillomavirus (HPV)-associated and independent patients. We solicited cases of molecularly or AFF2 immunohistochemistry (IHC) proven DEK::AFF2 SCC from surgical pathologists to collect patient demographic, clinical, and outcome data. Using representative H&E slides, we characterized the morphology and counted mitoses. Ki-67 immunohistochemistry was performed. We also compared the DEK::AFF2 survival rates to those in a cohort of AFF2 IHC-negative HPV-associated and HPV-independent SCC. DEK::AFF2 carcinomas most commonly arose in the nasal cavity (13/30, 43%), and the average number of recurrences was 1.8 (range: 0 to 10). At the last follow-up, most patients were disease free (19/30, 63%) or were alive with disease (9/30, 30%). There was an average mitotic rate of 2 per 2 mm2 (range: 0 to 9) and Ki-67 proliferation rate of 26% (range: 3% to 60%). Local recurrence was common, but morphology, mitotic activity, and Ki-67 index were not associated with recurrence or survival. On Kaplan-Meier survival analysis, DEK::AFF2 patients had lower disease-free survival but otherwise had similar outcomes to conventional SCC patients. Our multi-institutional study shows that local recurrence is common in DEK::AFF2 fusion nonkeratinizing SCC patients, but patients have survival rates similar to conventional SCC. Despite showing a range of different features and proliferation rates, traditional grading by morphology, mitotic rate, and/or Ki-67 activity does not seem to be predictive of outcome.